BioNTech (BNTX)
(Real Time Quote from BATS)
$113.84 USD
+1.33 (1.18%)
Updated Sep 20, 2024 10:26 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BNTX 113.84 +1.33(1.18%)
Will BNTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNTX
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
Other News for BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
BioNTech price target raised by $55 at Deutsche Bank, here's why
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life